Production (Stage)
CNS Pharmaceuticals, Inc.
CNSP
$0.811
$0.00370.46%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Total Cash And Short-Term Investments | 13.05M | 6.46M | 6.97M | 1.49M | 815.20K |
Total Receivables | -- | 882.50K | -- | -- | -- |
Inventory | -- | -- | -- | -- | -- |
Prepaid Expenses | 653.80K | 1.29M | 388.00K | 637.10K | 786.10K |
Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
Other Current Assets | 20.60K | 20.60K | 26.90K | 16.80K | -- |
Total Current Assets | 13.72M | 8.66M | 7.39M | 2.15M | 1.60M |
|
|||||
Total Current Assets | 13.72M | 8.66M | 7.39M | 2.15M | 1.60M |
Net Property, Plant & Equipment | 4.90K | 6.00K | 2.80K | 3.60K | 4.30K |
Long-term Investments | -- | -- | -- | -- | -- |
Goodwill | -- | -- | -- | -- | -- |
Total Other Intangibles | -- | -- | -- | -- | -- |
Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
Total Other Assets | 22.40K | 36.40K | 18.40K | 320.30K | 55.30K |
Total Assets | 13.75M | 8.70M | 7.41M | 2.47M | 1.66M |
|
|||||
Total Accounts Payable | 2.57M | 2.20M | 4.03M | 6.64M | 5.88M |
Total Accrued Expenses | -- | -- | -- | -- | -- |
Short-term Debt | 210.70K | 326.10K | 31.20K | 123.20K | 213.10K |
Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
Finance Division Debt Current | -- | -- | -- | -- | -- |
Total Finance Division Other Current Liabilities | -- | -- | -- | -- | -- |
Total Other Current Liabilities | -- | -- | -- | -- | -- |
Total Current Liabilities | 2.78M | 2.52M | 4.06M | 6.76M | 6.09M |
|
|||||
Total Current Liabilities | 2.78M | 2.52M | 4.06M | 6.76M | 6.09M |
Long-Term Debt | -- | -- | -- | -- | -- |
Short-term Debt | 210.70K | 326.10K | 31.20K | 123.20K | 213.10K |
Capital Leases | -- | -- | -- | -- | -- |
Finance Division Debt Non Current | -- | -- | -- | -- | -- |
Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
Total Other Liabilities | -- | -- | -- | -- | -- |
Total Liabilities | 2.78M | 2.52M | 4.06M | 6.76M | 6.09M |
|
|||||
Common Stock & APIC | 99.70M | 90.60M | 84.60M | 71.35M | 68.68M |
Retained Earnings | -88.73M | -84.42M | -81.25M | -75.64M | -73.11M |
Treasury Stock & Other | -- | -- | -- | -- | -- |
Total Common Equity | 10.97M | 6.18M | 3.35M | -4.29M | -4.43M |
|
|||||
Preferred Stock Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Convertible | -- | -- | -- | -- | -- |
Preferred Stock, Others | -- | -- | -- | -- | -- |
Total Preferred Equity | -- | -- | -- | -- | -- |
|
|||||
Total Common Equity | 10.97M | 6.18M | 3.35M | -4.29M | -4.43M |
Total Preferred Equity | -- | -- | -- | -- | -- |
Total Minority Interest | -- | -- | -- | -- | -- |
Total Equity | 10.97M | 6.18M | 3.35M | -4.29M | -4.43M |
|